HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

606.745

+27.3854.73%

Number of Gainers:29

Number of Losers:4

Number of Flat:1

PE:- -

High:611.657

Open:579.115

Low:567.229

Close:579.360

Volume:206.59M

Turnover:4.56B

Market Cap:385.85B

Float Cap:344.45B

Loading ...

Apichope Subsidiary's Novel Drug APH03571 Receives Clinical Trial Application Acceptance

UBS Trims Innocare Pharma Target to HK$19.8, Keeps Buy Rating

Tiansheng Pharmaceutical Faces Legal Claims Over Misstated Annual Reports, Some Cases Filed

Akeso Advances Next Generation Oncology Pipeline With New Trial Clearances

Simply Wall St.

Vincentage Pharma Mulls Hong Kong IPO with $100-200 Million Fundraising Target

Peijia Medical Reports Robust 2025 Performance with Steady Growth in Core Operations

Dingzhou Regulators Conduct Training on Medical Device Distribution Regulations

CLSA Raises Target Price for GENFLEET-B to HK$61.9, Keeps Outperform Rating

Robust Earnings Fuel Continued Gains for Hong Kong Stock Connect Biotech ETFs Amid Market Downturn

CSTONE PHARMA-B Shares Extend Gains Following Top ESMO Guideline Recommendation for Core Product

Long-Term Care Insurance System to Start at Municipal Level, Avoids Uniform Implementation

Ascentage Pharma's 2025 Loss Widens

MT Newswires Live

Peijia Medical Chairman Plans Up to HK$15 Million Share Purchase

MT Newswires Live

BRIEF-Peijia Medical Says Increase In Shareholding By CEO

BRIEF-Ascentage Pharma Group International Posts FY Loss Increased To RMB1,243 Million

Hang Seng Index Opens 0.27% Lower, Tech Index Drops 0.68%

ASCENTAGE-B Reports Strong Growth Driven by Dual Commercial Engines

EVEREST MED Reports Fiscal Year Performance with 141.51% Revenue Surge Driven by Strong Nefecon® Sales

Press Release: Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates

Everest Medicines FY2025 net loss narrows to RMB298 million; revenue more than doubled to RMB1.7 billion

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1574/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":606.74475,"timestamp":1774598898612,"preClose":579.3598,"halted":0,"volume":206587090,"delay":0,"changeRate":0.047268,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":27.384949,"latestTime":"03-27 16:00:00","open":579.1151,"high":611.6572,"low":567.22943,"amount":4555921928,"amplitude":0.076684,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774834200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774575000000,1774584000000],[1774587600000,1774598400000]],"pbRate":5.063104,"peRate":-71.030411,"turnoverRate":0.007466,"increases":29,"decrements":3,"flats":1,"marketCap":385851372864,"floatMarketCap":344445595920},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":611.6572,"amplitude":0.076684,"preClose":579.3598,"low":567.22943,"pbRate":"5.063104","latestPrice":606.74475,"volume":206587090,"delay":0,"open":579.1151,"prevYearClose":556.26263,"prevWeekClose":560.669,"prevMonthClose":553.496,"prevQuarterClose":556.263,"fiveDayClose":560.669,"twentyDayClose":553.496,"sixtyDayClose":561.301,"secType":"PLATE","market":"HK","turnoverRate":0.007466,"peRate":-71.030411,"marketCap":385851372864,"floatMarketCap":344445595920,"timestamp":1774598898612,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":29,"down":4,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1102856541","title":"Apichope Subsidiary's Novel Drug APH03571 Receives Clinical Trial Application Acceptance","url":"https://stock-news.laohu8.com/highlight/detail?id=1102856541","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102856541?lang=en_us&edition=fundamental","pubTime":"2026-03-26 16:28","pubTimestamp":1774513724,"startTime":"0","endTime":"0","summary":"Apichope Pharmaceutical Group Co., Ltd. (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Apichope Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","06978","BK1161","300723","BK0239","BK1574"],"gpt_icon":0},{"id":"1127956704","title":"UBS Trims Innocare Pharma Target to HK$19.8, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1127956704","media":"Stock News","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127956704?lang=en_us&edition=fundamental","pubTime":"2026-03-26 16:18","pubTimestamp":1774513124,"startTime":"0","endTime":"0","summary":"UBS has revised its forecasts for Innocare Pharma (09969), lowering sales projections for 2026 and 2027 while increasing expense estimates. This adjustment reduces the earnings per share forecast for...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969","BK0239","BK1161","BK1574","688428"],"gpt_icon":0},{"id":"1171219051","title":"Tiansheng Pharmaceutical Faces Legal Claims Over Misstated Annual Reports, Some Cases Filed","url":"https://stock-news.laohu8.com/highlight/detail?id=1171219051","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171219051?lang=en_us&edition=fundamental","pubTime":"2026-03-26 15:50","pubTimestamp":1774511442,"startTime":"0","endTime":"0","summary":"Investors who suffered losses can register their claims against the company through the Sina Investor Rights Protection Platform. A batch of cases has recently been submitted to the court for filing...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01477","BK1574"],"gpt_icon":0},{"id":"2622858681","title":"Akeso Advances Next Generation Oncology Pipeline With New Trial Clearances","url":"https://stock-news.laohu8.com/highlight/detail?id=2622858681","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622858681?lang=en_us&edition=fundamental","pubTime":"2026-03-26 15:07","pubTimestamp":1774508839,"startTime":"0","endTime":"0","summary":"Akeso received regulatory clearance in China to start Phase II trials for two next generation antibody drug conjugates, AK146D1 and AK138D1, in oncology.\nThe company also secured clearance for AK150, a globally first in class trispecific antibody, to begin clinical trials in patients with advanced solid tumors.\nThese approvals move multiple assets in Akeso's pipeline into clinical and mid stage development.\n\nFor investors tracking Akeso (SEHK:9926), these clearances come with the stock...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-advances-next-generation-oncology-pipeline-with-new-tr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-advances-next-generation-oncology-pipeline-with-new-tr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1961090484.USD","LU0348783233.USD","LU0348735423.USD","LU0561508036.HKD","LU2476274720.SGD","LU0417516571.SGD","LU2488822045.USD","IE00B543WZ88.USD","LU0348825331.USD","LU0348827113.USD","LU0540923850.HKD","09926","LU1720050803.USD","LU0417516738.SGD","LU0634319403.HKD","LU0348784397.USD","LU0348767384.USD","LU2778985437.USD","BK1574","IE00B5MMRT66.SGD","BK1161","IE00BPRC5H50.USD","LU0417516902.SGD","LU2399975544.HKD","LU2476274308.USD","LU0348766576.USD","LU1794554557.SGD"],"gpt_icon":0},{"id":"1150686184","title":"Vincentage Pharma Mulls Hong Kong IPO with $100-200 Million Fundraising Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1150686184","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150686184?lang=en_us&edition=fundamental","pubTime":"2026-03-26 14:28","pubTimestamp":1774506505,"startTime":"0","endTime":"0","summary":"Vincentage Pharma, a Chengdu-based pharmaceutical technology company, is reportedly considering a listing on the Hong Kong stock exchange. The company aims to raise between $100 million and $200...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","09939","159938","BK1574"],"gpt_icon":0},{"id":"1144506030","title":"Peijia Medical Reports Robust 2025 Performance with Steady Growth in Core Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=1144506030","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144506030?lang=en_us&edition=fundamental","pubTime":"2026-03-26 13:31","pubTimestamp":1774503081,"startTime":"0","endTime":"0","summary":"Peijia Medical Limited (Stock Code: 09996) announced its audited annual results for the twelve months ended December 31, 2025, on March 25, 2026. Throughout the 2025 fiscal year, the Group adhered to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159891","BK1583","BK1574","09996","BK1100"],"gpt_icon":0},{"id":"1192091170","title":"Dingzhou Regulators Conduct Training on Medical Device Distribution Regulations","url":"https://stock-news.laohu8.com/highlight/detail?id=1192091170","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192091170?lang=en_us&edition=fundamental","pubTime":"2026-03-26 13:30","pubTimestamp":1774503024,"startTime":"0","endTime":"0","summary":"The market regulator in Dingzhou City, Hebei Province, recently organized a three-session training program on regulations governing the medical device distribution sector for 156 local medical device...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159883","BK1583","BK1574","09997","BK1100","09996","BK1222"],"gpt_icon":0},{"id":"1132923572","title":"CLSA Raises Target Price for GENFLEET-B to HK$61.9, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1132923572","media":"Stock News","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132923572?lang=en_us&edition=fundamental","pubTime":"2026-03-26 11:17","pubTimestamp":1774495045,"startTime":"0","endTime":"0","summary":"CLSA released a research report indicating that GENFLEET-B (02595) reported revenue of RMB 130 million last year, a year-on-year increase of 24.42%. R&D expenses were RMB 282 million, down 15.01%...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","02595","BK1574","09939","159938"],"gpt_icon":0},{"id":"1199006540","title":"Robust Earnings Fuel Continued Gains for Hong Kong Stock Connect Biotech ETFs Amid Market Downturn","url":"https://stock-news.laohu8.com/highlight/detail?id=1199006540","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199006540?lang=en_us&edition=fundamental","pubTime":"2026-03-26 11:11","pubTimestamp":1774494703,"startTime":"0","endTime":"0","summary":"On March 26, Hong Kong Stock Connect pharmaceutical stocks demonstrated resilience against the broader market trend. The Huabao Hong Kong Stock Connect Innovative Drug ETF (520880), which focuses...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VXUS","BK1161","159992","02157","BK1574","520880","BK4588","06978"],"gpt_icon":0},{"id":"1163282057","title":"CSTONE PHARMA-B Shares Extend Gains Following Top ESMO Guideline Recommendation for Core Product","url":"https://stock-news.laohu8.com/highlight/detail?id=1163282057","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163282057?lang=en_us&edition=fundamental","pubTime":"2026-03-26 10:58","pubTimestamp":1774493905,"startTime":"0","endTime":"0","summary":"CSTONE PHARMA-B (02616) saw its shares rise more than 4% again. At the time of writing, the stock was up 3.77% to HK$7.14, with a turnover of HK$35.6465 million. The movement follows an announcement...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02616","BK4585","BK1161","VXUS","BK4588"],"gpt_icon":0},{"id":"1193641812","title":"Long-Term Care Insurance System to Start at Municipal Level, Avoids Uniform Implementation","url":"https://stock-news.laohu8.com/highlight/detail?id=1193641812","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193641812?lang=en_us&edition=fundamental","pubTime":"2026-03-26 10:50","pubTimestamp":1774493456,"startTime":"0","endTime":"0","summary":"On March 26, financial sources reported that the State Council Information Office held a press conference to discuss the acceleration of establishing a long-term care insurance system. Huang Xinyu,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","09939","BK1574","BK1161","159938"],"gpt_icon":0},{"id":"2622882621","title":"Ascentage Pharma's 2025 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2622882621","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622882621?lang=en_us&edition=fundamental","pubTime":"2026-03-26 10:43","pubTimestamp":1774492985,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International  booked 1.24 billion yuan in attributable loss for 2025, widening from a loss of 405.4 million yuan in 2024, according to a Hong Kong bourse filing Thursday.Loss per share was 3.49 yuan, compared with 1.34 yuan in the prior year.Revenue fell to 574.1 million yuan, compared with 980.7 million yuan in 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","06855","BK1574"],"gpt_icon":0},{"id":"2622884268","title":"Peijia Medical Chairman Plans Up to HK$15 Million Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2622884268","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622884268?lang=en_us&edition=fundamental","pubTime":"2026-03-26 10:20","pubTimestamp":1774491632,"startTime":"0","endTime":"0","summary":"Peijia Medical (HKG:9996) said Chairman and CEO Yi Zhang plans to increase his shareholding via on-market purchases starting Thursday, according to a same-day Hong Kong bourse filing.The purchases, to be made through his controlled corporation, are expected to total up to HK$15 million.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","BK1100","09996","BK1583"],"gpt_icon":0},{"id":"2622817898","title":"BRIEF-Peijia Medical Says Increase In Shareholding By CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2622817898","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622817898?lang=en_us&edition=fundamental","pubTime":"2026-03-26 09:55","pubTimestamp":1774490100,"startTime":"0","endTime":"0","summary":"BRIEF-Peijia Medical Says Increase In Shareholding By CEOMarch 26 (Reuters) - Peijia Medical Ltd 9996.HK:INCREASE IN SHAREHOLDING BY CEOCEO SHAREHOLDING INCREASE NOT EXPECTED TO EXCEED HK$15 MILLIONFurther company coverage: 9996.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40D192:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","09996","BK1583","BK1574"],"gpt_icon":0},{"id":"2622881522","title":"BRIEF-Ascentage Pharma Group International Posts FY Loss Increased To RMB1,243 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622881522","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622881522?lang=en_us&edition=fundamental","pubTime":"2026-03-26 09:35","pubTimestamp":1774488950,"startTime":"0","endTime":"0","summary":"BRIEF-Ascentage Pharma Group International Posts FY Loss Increased To RMB1,243 MillionMarch 26 (Reuters) - Ascentage Pharma Group International 6855.HK:FY LOSS INCREASED TO RMB1,243 MILLIONFurther company coverage: 6855.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40D121:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","06855"],"gpt_icon":0},{"id":"1156005972","title":"Hang Seng Index Opens 0.27% Lower, Tech Index Drops 0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156005972","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156005972?lang=en_us&edition=fundamental","pubTime":"2026-03-26 09:35","pubTimestamp":1774488907,"startTime":"0","endTime":"0","summary":"U.S. stocks advanced on Wednesday as signs of easing tensions in the Middle East and a pullback in oil prices from recent highs improved market sentiment. All three major indices closed higher. The...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b24215200193ae69a7d1d1beb4a9885c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSTECH","BK1095","LU0348767384.USD","LU0307460666.USD","HTImain","LU0463099449.HKD","LU0572944931.SGD","LU1023057109.AUD","02833","LU1719994722.HKD","LU2097828631.EUR","LU1720050803.USD","BK1574","LU0348766576.USD","LU1770034418.SGD","MCHmain","01024","LU0359202008.SGD","LU1794554557.SGD","LU0140636845.USD","BK1615","BK1608","LU0326950275.SGD","BK1575","BK1591","LU0359201885.HKD","LU0359201612.USD","HHImain","HSI","LU0327786744.USD","LU1251922891.USD","513600","LU1303224171.USD","LU0210526637.USD","81024","HSImain","LU1188198961.HKD","LU2097828805.USD","LU2097828557.USD","LU0588546209.SGD","LU0051755006.USD","LU2097828714.EUR","BK1610","LU0211977185.USD","LU0244354667.USD","LU0593848301.USD","LU2097828474.EUR","BK1161","LU0456827905.SGD","BK1590"],"gpt_icon":1},{"id":"1189397132","title":"ASCENTAGE-B Reports Strong Growth Driven by Dual Commercial Engines","url":"https://stock-news.laohu8.com/highlight/detail?id=1189397132","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189397132?lang=en_us&edition=fundamental","pubTime":"2026-03-26 07:32","pubTimestamp":1774481547,"startTime":"0","endTime":"0","summary":"On March 26, leading innovative drug company ASCENTAGE PHARMA GROUP released its full-year 2025 results. During the reporting period, the company achieved total revenue of 574 million Chinese yuan,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06855","BK1574","AAPG","BK4139"],"gpt_icon":0},{"id":"1158335307","title":"EVEREST MED Reports Fiscal Year Performance with 141.51% Revenue Surge Driven by Strong Nefecon® Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=1158335307","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158335307?lang=en_us&edition=fundamental","pubTime":"2026-03-26 07:30","pubTimestamp":1774481434,"startTime":"0","endTime":"0","summary":"EVEREST MED (01952) announced its annual results for the period ending December 31, 2025. The group recorded revenue of RMB 1.707 billion, representing a year-on-year increase of 141.51%. The loss...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK1161","01952"],"gpt_icon":0},{"id":"2622888069","title":"Press Release: Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2622888069","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622888069?lang=en_us&edition=fundamental","pubTime":"2026-03-26 07:00","pubTimestamp":1774479600,"startTime":"0","endTime":"0","summary":"-- Product sales and commercial rights revenues in 2025 increased 90%. -- Sales of Olverembatinib increased 81% year-over-year to US$62.2 million. -- Sales of Lisaftoclax since launch during last five months of 2025 were. Dr. Dajun Yang, Chairman and Chief Executive Officer of Ascentage Pharma, said, \"2025 was a year of significant execution in advancing our mission to deliver innovative therapies to patients worldwide. We advanced our commercialization strategy as Olverembatinib gained significant traction after receiving NRDL coverage expansion, which has markedly enhanced affordability and accessibility for patients in China. We launched Lisaftoclax in China in late July 2025 shortly after receiving regulatory approval and are gaining market adoption as we actively pursue the inclusion of Lisaftoclax in China's NRDL.\". Olverembatinib  is a novel, next-generation TKI and the first third-generation BCR-ABL1 TKI approved in China for treatment of patients with chronic myeloid leukemia ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","5BI.SI","LU1223083913.SGD","PK","BK4017","BK6514","LU1223082196.USD","LABU","BK4588","AAPG","06855","BK6008","CDE","BK1574","EMA","BK4218","BK4585","LU1223082519.USD","BK4081","BK4181","BK4139"],"gpt_icon":0},{"id":"2622882758","title":"Everest Medicines FY2025 net loss narrows to RMB298 million; revenue more than doubled to RMB1.7 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2622882758","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622882758?lang=en_us&edition=fundamental","pubTime":"2026-03-26 06:55","pubTimestamp":1774479323,"startTime":"0","endTime":"0","summary":"Everest Medicines published an annual results announcement for the year ended Dec. 31, 2025.Revenue was RMB1.71 billion, more than tripled, driven mainly by the continued ramp-up of NEFECON following its inclusion in China’s NRDL.Net loss was RMB297.8 million, down 71.4%, attributed to revenue growth, improved efficiency, deferred tax asset recognition in Singapore, and RMB312.3 million of impairment losses on intangible assets.Cash and cash equivalents and bank deposits were RMB2.73 billion, and adjusted profit was RMB187.2 million; management said it plans to pursue NRDL negotiations in 2H 2026 for VELSIPITY and XERAVA and expects to submit a China BLA in 1H 2026 for LEROCHOL.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Me","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL4gxd68:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1161","01952","BK1574"],"gpt_icon":0}],"pageSize":20,"totalPage":19,"pageCount":6,"totalSize":369,"code":"91000000","status":"200"}]}}